IDO inhibitors are sure to be a hot topic at the upcoming American Society of Clinical Oncology annual meeting, with Incyte Corp. at the lead, in partnership with Merck & Co. and Bristol-Myers Squibb Co.
For More ASCO Picks
(Also see "It's Not All About IO: Seven Drugs To Watch At ASCO" - Scrip, 19 May, 2017.)
PD-1/L1 inhibitors can go only so far in immunotherapy, which is why there is so much focus on potential combinations....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?